OBJECTIVES: New antibiotics that are active against multidrug-resistant (MDR) Acinetobacter baumannii are urgently needed. BAL30072, a siderophore monosulfactam antibiotic that rapidly penetrates the outer membrane of A. baumannii and has potent activity against most isolates, including those harbouring AmpC β-lactamases and metallo- (class B) or OXA- (class D) carbapenemases, is being developed to meet that need. METHODS: We assessed the in vitro activity of BAL30072, meropenem and the combination of BAL30072 and meropenem (2:1 and 1:1 ratios) by MIC and time-kill studies. Proof-of-principle in vivo efficacy was determined using a rat soft-tissue infection model. Five diverse strains with defined phenotypic and genetic profiles were tested (AB307-0294, AB8407, AB1697, AB3340 and AB0057). RESULTS: In microdilution assays, combining BAL30072 with meropenem lowered meropenem MICs 2-8-fold. In time-kill studies, the BAL30072 and meropenem combinations resulted in bactericidal concentrations 2-8-fold lower than those of meropenem or BAL30072 alone. In the rat model, BAL30072 was active against four of five strains (AB307-0294, AB8407, AB1697 and AB3340), including meropenem-susceptible and -non-susceptible strains. AB0057 was the only strain resistant to BAL30072 in vivo and in vitro (MIC >64 mg/L). Meropenem was active in vivo against two of the five strains tested (AB307-0294 and AB3340). Both BAL30072 and BAL30072 with meropenem were equally effective in vivo. CONCLUSIONS: These data support the continued evaluation of BAL30072 for use in the treatment of infections caused by MDR A. baumannii.
OBJECTIVES: New antibiotics that are active against multidrug-resistant (MDR) Acinetobacter baumannii are urgently needed. BAL30072, a siderophore monosulfactam antibiotic that rapidly penetrates the outer membrane of A. baumannii and has potent activity against most isolates, including those harbouring AmpC β-lactamases and metallo- (class B) or OXA- (class D) carbapenemases, is being developed to meet that need. METHODS: We assessed the in vitro activity of BAL30072, meropenem and the combination of BAL30072 and meropenem (2:1 and 1:1 ratios) by MIC and time-kill studies. Proof-of-principle in vivo efficacy was determined using a rat soft-tissue infection model. Five diverse strains with defined phenotypic and genetic profiles were tested (AB307-0294, AB8407, AB1697, AB3340 and AB0057). RESULTS: In microdilution assays, combining BAL30072 with meropenem lowered meropenem MICs 2-8-fold. In time-kill studies, the BAL30072 and meropenem combinations resulted in bactericidal concentrations 2-8-fold lower than those of meropenem or BAL30072 alone. In the rat model, BAL30072 was active against four of five strains (AB307-0294, AB8407, AB1697 and AB3340), including meropenem-susceptible and -non-susceptible strains. AB0057 was the only strain resistant to BAL30072 in vivo and in vitro (MIC >64 mg/L). Meropenem was active in vivo against two of the five strains tested (AB307-0294 and AB3340). Both BAL30072 and BAL30072 with meropenem were equally effective in vivo. CONCLUSIONS: These data support the continued evaluation of BAL30072 for use in the treatment of infections caused by MDR A. baumannii.
Authors: Z Jerassy; A M Yinnon; S Mazouz-Cohen; S Benenson; Y Schlesinger; B Rudensky; D Raveh Journal: J Hosp Infect Date: 2005-11-22 Impact factor: 3.926
Authors: S K Tanaka; R A Summerill; B F Minassian; K Bush; D A Visnic; D P Bonner; R B Sykes Journal: Antimicrob Agents Chemother Date: 1987-02 Impact factor: 5.191
Authors: Maria Cristina Bronharo Tognim; Soraya Sgambatti Andrade; Suzane Silbert; Ana Cristina Gales; Ronald N Jones; Hélio S Sader Journal: Int J Infect Dis Date: 2004-09 Impact factor: 3.623
Authors: David Landman; John M Quale; David Mayorga; Adedeyo Adedeji; Kalyani Vangala; Jayshree Ravishankar; Carlos Flores; Steven Brooks Journal: Arch Intern Med Date: 2002-07-08
Authors: Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert Journal: Clin Infect Dis Date: 2013-04-17 Impact factor: 9.079
Authors: Lucile Moynié; Alexandre Luscher; Dora Rolo; Daniel Pletzer; Antoni Tortajada; Helge Weingart; Yvonne Braun; Malcolm G P Page; James H Naismith; Thilo Köhler Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Mitchell G Thompson; Vu Truong-Le; Yonas A Alamneh; Chad C Black; Jeff Anderl; Cary L Honnold; Rebecca L Pavlicek; Rania Abu-Taleb; Matthew C Wise; Eric R Hall; Eric J Wagar; Eric Patzer; Daniel V Zurawski Journal: Antimicrob Agents Chemother Date: 2015-08-03 Impact factor: 5.191